BioCurity, Inc. was founded in 2010 to provide therapeutic solutions for treating cancers. While the company plans on developing a portfolio of cancer therapies over the next several years, BioCurity’s first product is a nanoparticle formulation, called RadGuard™, which simply and quickly protects people from radiation exposure, including exposure that is the norm in radiation treatments for cancers.  BioCurity’s radiation protection intellectual property portfolio is based upon research conducted by Dr. Cheryl Baker, BioCurity’s scientific founder and the former director of MD Anderson Cancer Center Orlando’s Cancer Research Institute. Dr. Baker’s initial research with the RadGuard™ nanoparticle has shown very positive results in selectively protecting healthy tissues from radiation damage while allowing radiation treatments to attack cancerous tissues.

BioCurity will jointly pursue both the medical and military markets since both are in need of selective radiation damage protection and mitigation solutions. While there have been some recent advances in therapies focused on radiation protection and mitigation, BioCurity is unique in two ways. First, BioCurity’s RadGuard™ product is unique in its ability to selectively protect healthy tissues while allowing radiation therapy to destroy cancer cells. Second, BioCurity is the first company to offer a topical cream version of its radiation mitigation product. All other competitive solutions require an injection-based formulation, which has a reduced shelf life and that has limitations in its ability to be carried by military field personnel. Because there are certain scenarios in which an injection-based product is preferred (to protect organs and deep tissues), BioCurity has also developed an injection-based version of its RadGuard™ formula.